Determination of Anti-Hib Type B Antibodies Level and Vaccination Coverage in Children Aged 6-7 Months, 18 Months After the Introduction of the Hib Vaccine in the District of Bamako-Mali

The Center for Vaccine Development – Mali as part of its hospital-based on surveillance of invasive bacterial infections in pediatrics at the Gabriel TOURE University Hospital, Hib was isolated in 10% of these children. It was in view of this opportunity to introduce the vaccine into the expanded vaccination program in 2005 that the Center for Vaccine Development – Mali decided to carry out studies. The objective of our study was to determine the level of anti-Hib Ab and vaccination coverage. This was a descriptive and cross-sectional study focusing on the measurement of anti-Hib antibodies and vaccination coverage in children aged 6-7 months to 18 months after introduction of the Hib vaccine in the Bamako district. The following results were obtained: 91.8% of participants' vaccination cards were presented, according to the mother's declaration or vaccination card. A gradual decrease in the percentage from the first to the third dose of DPT, OPV, hepatitis B and Hib was noted. Among our participants, 81.4% were correctly vaccinated and therefore had received all the antigens (BCG, OPV, Pentavalent). The obstacle was the reason most cited by mothers for not vaccinating their children in both surveys. 70% of participants had an antibody level greater than or equal to the value considered as the protection threshold which is 1.0mcg/ml 18 months after introduction of the Hib vaccine.